Holmes Chapel, UK, Bespak, the specialist inhalation CDMO, has achieved a Gold EcoVadis sustainability rating for its Holmes Chapel site. The result places Bespak among the top 5% of companies assessed worldwide.

“Bespak is proud to once again achieve the EcoVadis Gold rating for our Holmes Chapel site. This recognition highlights our long-term commitment to maintaining high standards and driving continued progress in sustainability across every aspect of our business.” Says Chris Hirst, CEO of Bespak. “Over the past year, we secured Science Based Targets initiative (SBTi) validation of our greenhouse gas reduction targets and established a clear roadmap to achieve net zero, supported by measurable targets and accountability across the organization.”

EcoVadis is a trusted provider of business sustainability ratings that has evaluated the sustainability management systems of over 150,000+ organisations around the globe. Its evidence-based framework evaluates performance across four key areas: environment, labor and human rights, ethics, and sustainable procurement.

This marks the 2nd Gold EcoVadis rating for Bespak’s Holmes Chapel site, and the first Gold rating since Bespak became an independent global CDMO focused on inhaled and nasal drug delivery.

Ahead of this year’s assessment, Bespak strengthened its sustainability management system by conducting a gap analysis, standardizing policy documentation across the organization, and expanding employee sustainability training to include carbon reduction, biodiversity and life cycle assessment. The company also launched its first supplier sustainability engagement workshop in September 2025, bringing together strategic suppliers to align on evolving sustainability expectations.

Benedicta A. Bakpa, Head of ESG at Bespak, said: “Bespak’s Gold EcoVadis rating has been awarded at a time when we are working hard to champion the transition to low carbon pressurized Metered Dose Inhalers (pMDIs) in the wider industry. This rating demonstrates our commitment to strong sustainability performance, operational consistency, and continuous improvement. It is the latest in a long line of exciting milestones for Bespak and we look forward to many more.”

Bespak publishes an annual ESG Report and discloses its sustainability performance through EcoVadis. Its greenhouse gas reduction targets have been validated by the SBTi and independent verification of emissions baselines by the Carbon Trust. Bespak also aligns its reporting with the GRI Standards, SASB guidelines, the UN Global Compact’s Ten Principles and the Global Biodiversity Framework

About Bespak

Bespak is a specialist global contract development and manufacturing organization (CDMO) solely focused on the inhaled and nasal drug delivery industry. It develops and manufactures inhaled and nasal drug products, drug delivery devices and components for the global pharmaceutical market. Headquartered in Holmes Chapel, UK, Bespak provides a specialist, fully integrated service to support customers from early-stage feasibility, analytical and formulation, product development and clinical supply, through to full-scale cGMP batch production.

With a long history in the development and commercial supply of pressurized Metered Dose Inhalers (pMDIs), Bespak supplies a major proportion of the world’s pMDI dosing valves and actuators. Built on established expertise but ready for the future, Bespak is a long-term innovation partner committed to driving sustainability in the industry. The company has both established capacity and ongoing expansions to enable the manufacture of pMDIs with low Global Warming Potential (GWP) propellants, making it well positioned to lead the green pMDI transition.

More information: www.bespak.com